{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:28:05Z","timestamp":1793212085799,"version":"4.5.0"},"reference-count":105,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background &amp; Aims<\/jats:title>\n                    <jats:p>The expanding use of advanced IBD therapies creates an urgent need for pregnancy safety data. While anti-TNF safety is well-established, evidence for newer agents (vedolizumab, ustekinumab, and JAK inhibitors) remains limited. We aimed to quantify adverse pregnancy outcomes among women exposed to advanced therapies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Random-effects models were used to calculate pooled prevalence estimates, with subgroup analyzes by therapeutic class. Restricted cubic spline meta-regression evaluated maternal age, disease activity, disease duration, phenotype, and third-trimester exposure as moderators.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>67 observational studies with 17\u2009441 pregnancies were included. Overall pooled prevalence rates were 8.2% (95% CI, 6.2-10.8) for early pregnancy loss, 8.9% (95% CI, 7.9-10.0) for preterm birth, 0.3% (95% CI, 0.2-0.6) for stillbirth, 6.6% (95% CI, 5.5-7.8) for low birth weight, 2.9% (95% CI, 2.2-3.9) for congenital malformations. JAK inhibitors and ustekinumab exposures were associated with higher pooled prevalence estimates of early pregnancy loss, while vedolizumab exposure was associated with higher estimates of preterm birth. Meta-regression identified disease duration, third-trimester exposure, maternal age, active disease, and Crohn\u2019s disease proportion as significant moderators of selected outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Advanced IBD therapies demonstrate an overall favorable safety profile. Active disease, older maternal age, and longer disease duration were significant predictors of complications. Associations with third-trimester exposure do not support routine discontinuation, as this likely reflects underlying disease severity rather than treatment effect, reinforcing the priority of maintaining remission during pregnancy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjag035","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:00:11Z","timestamp":1774364411000},"source":"Crossref","is-referenced-by-count":4,"title":["Safety of advanced therapies in pregnant women with inflammatory bowel disease: a systematic review and Meta-Analysis"],"prefix":"10.1093","volume":"20","author":[{"given":"Bernardo de Faria","family":"Moraes","sequence":"first","affiliation":[{"name":"Universidade Federal de Minas Gerais School of Medicine, , Belo Horizonte,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Andr\u00e9 Pedral Diniz","family":"Leite","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais School of Medicine, , Belo Horizonte,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa Medeiros","family":"Visentini","sequence":"additional","affiliation":[{"name":"Universidade do Oeste Paulista School of Medicine, , Presidente Prudente,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriel Andr\u00e9 Pedral Diniz","family":"Leite","sequence":"additional","affiliation":[{"name":"Universidade Federal de Minas Gerais School of Medicine, , Belo Horizonte,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor Boechat","family":"Silveira","sequence":"additional","affiliation":[{"name":"Universidade Federal de Juiz de Fora School of Medicine, , Juiz de Fora,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valbert Oliveira Costa","family":"Filho","sequence":"additional","affiliation":[{"name":"Universidade Federal do Cear\u00e1 School of Medicine, , Fortaleza,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Pedro Possapp","family":"Beis","sequence":"additional","affiliation":[{"name":"Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul School of Medicine, , Porto Alegre,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo Corr\u00eaa","family":"S\u00fcffert","sequence":"additional","affiliation":[{"name":"Pontif\u00edcia Universidade Cat\u00f3lica do Rio Grande do Sul School of Medicine, , Porto Alegre,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro Robson Costa","family":"Passos","sequence":"additional","affiliation":[{"name":"Universidade Federal do Cear\u00e1 School of Medicine, , Fortaleza,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7824-2152","authenticated-orcid":false,"given":"Guilherme Grossi Lopes","family":"Can\u00e7ado","sequence":"additional","affiliation":[{"name":"Hospital das Cl\u00ednicas da Universidade Federal de Minas Gerais Instituto Alfa de Gastroenterologia, , Belo Horizonte,","place":["Brazil"]},{"name":"Hospital da Pol\u00edcia Militar de Minas Gerais Department of Gastroenterology and Hepatology, , Belo Horizonte,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,3,24]]},"reference":[{"key":"2026032411000531200_jjag035-B1","doi-asserted-by":"publisher","first-page":"e0331034","DOI":"10.1371\/journal.pone.0331034","article-title":"Global disease burden of inflammatory bowel disease in women and women of childbearing age from 1990 to 2021 and its prediction to 2040","volume":"20","author":"Zhao","year":"2025","journal-title":"PLoS One"},{"key":"2026032411000531200_jjag035-B2","doi-asserted-by":"publisher","first-page":"e5648","DOI":"10.7759\/cureus.5648","article-title":"The impact of inflammatory bowel disease on pregnancy and the fetus: a literature review","volume":"11","author":"Pervez","year":"2019","journal-title":"Cureus"},{"key":"2026032411000531200_jjag035-B3","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1093\/ecco-jcc\/jjaa225","article-title":"The influence of disease activity on pregnancy outcomes in women with inflammatory bowel disease: a systematic review and meta-Analysis","volume":"15","author":"Kim","year":"2021","journal-title":"J Crohns Colitis"},{"key":"2026032411000531200_jjag035-B4","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/S0140-6736(24)00052-7","article-title":"Updates on the management of inflammatory bowel disease from periconception to pregnancy and lactation","volume":"403","author":"Nielsen","year":"2024","journal-title":"Lancet"},{"key":"2026032411000531200_jjag035-B5","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1093\/ibd\/izaf171","article-title":"Global consensus statement on the management of pregnancy in inflammatory bowel disease","volume":"31","author":"Mahadevan","year":"2025","journal-title":"Inflamm Bowel Dis"},{"key":"2026032411000531200_jjag035-B6","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.cgh.2020.09.021","article-title":"Biologics for inflammatory bowel disease and their safety in pregnancy: a systematic review and meta-analysis","volume":"20","author":"Nielsen","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026032411000531200_jjag035-B7","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1016\/j.dld.2024.06.011","article-title":"Risk of anti-TNF therapy on pregnancy, breastfeeding, live vaccines and related information in patients with inflammatory bowel disease: real-world data from a nationwide study","volume":"56","author":"Bendaoud","year":"2024","journal-title":"Dig Liver Dis"},{"key":"2026032411000531200_jjag035-B8","doi-asserted-by":"publisher","first-page":"e44393","DOI":"10.1097\/MD.0000000000044393","article-title":"Comparative safety of ustekinumab versus anti-TNF therapy during pregnancy in patients with inflammatory bowel disease: a systematic review and meta-analysis","volume":"104","author":"Bardak","year":"2025","journal-title":"Medicine (Baltimore)"},{"key":"2026032411000531200_jjag035-B9","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1111\/jgh.15574","article-title":"Systematic review and meta-analysis: safety of vedolizumab during pregnancy in patients with inflammatory bowel disease","volume":"36","author":"Bell","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"2026032411000531200_jjag035-B10","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026032411000531200_jjag035-B11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan-a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"2026032411000531200_jjag035-B12","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1097\/XEB.0000000000000054","article-title":"Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data","volume":"13","author":"Munn","year":"2015","journal-title":"Int J Evid Based Healthc"},{"key":"2026032411000531200_jjag035-B13","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/EDE.0000000000001232","article-title":"Meta-analysis of proportions using generalized linear mixed models","volume":"31","author":"Lin","year":"2020","journal-title":"Epidemiology"},{"key":"2026032411000531200_jjag035-B14","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1002\/jrsm.1521","article-title":"Synthesis of evidence from zero-events studies: a comparison of one-stage framework methods","volume":"13","author":"Xu","year":"2022","journal-title":"Res Synth Methods"},{"key":"2026032411000531200_jjag035-B15","doi-asserted-by":"publisher","author":"Harrell","year":"2009","DOI":"10.32614\/cran.package.rms"},{"key":"2026032411000531200_jjag035-B16","doi-asserted-by":"publisher","first-page":"1283705","DOI":"10.3389\/fepid.2023.1283705","article-title":"Greedy knot selection algorithm for restricted cubic spline regression","volume":"3","author":"Arnes","year":"2023","journal-title":"Front Epidemiol"},{"key":"2026032411000531200_jjag035-B17","doi-asserted-by":"publisher","author":"Viechtbauer","year":"2009","DOI":"10.32614\/cran.package.metafor"},{"key":"2026032411000531200_jjag035-B18","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1186\/1471-2288-14-135","article-title":"Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range","volume":"14","author":"Wan","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"2026032411000531200_jjag035-B19","author":"Phillips"},{"key":"2026032411000531200_jjag035-B20","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/s0895-4356(01)00377-8","article-title":"Funnel plots for detecting bias in meta-analysis: guidelines on choice of axis","volume":"54","author":"Sterne","year":"2001","journal-title":"J Clin Epidemiol"},{"key":"2026032411000531200_jjag035-B21","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"key":"2026032411000531200_jjag035-B22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","article-title":"How to perform a meta-analysis with R: a practical tutorial","volume":"22","author":"Balduzzi","year":"2019","journal-title":"Evid Based Ment Health"},{"key":"2026032411000531200_jjag035-B23","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"2026032411000531200_jjag035-B24","doi-asserted-by":"publisher","first-page":"otac025","DOI":"10.1093\/crocol\/otac025","article-title":"Ustekinumab exposure in pregnant women from inflammatory bowel disease clinical trials: pregnancy outcomes through up to 5 Years in Crohn\u2019s Disease and 2 years in ulcerative colitis","volume":"4","author":"Abraham","year":"2022","journal-title":"Crohns Colitis 360"},{"key":"2026032411000531200_jjag035-B25","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1007\/s00404-022-06463-x","article-title":"Pregnant women with immune mediated inflammatory diseases who discontinue biologics have higher rates of disease flare","volume":"306","author":"Allen","year":"2022","journal-title":"Arch Gynecol Obstet"},{"key":"2026032411000531200_jjag035-B26","doi-asserted-by":"publisher","first-page":"59","DOI":"10.4321\/s1130-01082012000200003","article-title":"Is safety infliximb during pregnancy in patients with inflammatory bowel disease?","volume":"104","author":"Arg\u00fcelles-Arias","year":"2012","journal-title":"Rev Esp Enferm Dig"},{"key":"2026032411000531200_jjag035-B27","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13247710","article-title":"Pregnancy in inflammatory bowel disease: data from a real-world cohort in Germany","volume":"13","author":"Ayoub","year":"2024","journal-title":"J Clin Med"},{"key":"2026032411000531200_jjag035-B28","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/pds.4930","article-title":"Anti-TNF treatment during pregnancy and birth outcomes: a population-based study from Denmark, Finland, and Sweden","volume":"29","author":"Br\u00f6ms","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2026032411000531200_jjag035-B29","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/ajg.2012.430","article-title":"Safety of thiopurines and anti-TNF-\u03b1 drugs during pregnancy in patients with inflammatory bowel disease","volume":"108","author":"Casanova","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"2026032411000531200_jjag035-B30","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/ajg.2017.501","article-title":"Long-term safety of in utero exposure to anti-TNF\u03b1 drugs for the treatment of inflammatory bowel disease: results from the multicenter European TEDDY study","volume":"113","author":"Chaparro","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2026032411000531200_jjag035-B31","doi-asserted-by":"publisher","first-page":"468","DOI":"10.14309\/ajg.0000000000002553","article-title":"Maternal and neonatal outcomes in Vedolizumab- and Ustekinumab-exposed pregnancies: results from the PIANO registry","volume":"119","author":"Chugh","year":"2024","journal-title":"Am J Gastroenterol"},{"key":"2026032411000531200_jjag035-B32","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/apt.12936","article-title":"Maternal and foetal adverse events with tumour necrosis factor-alpha inhibitors in inflammatory bowel disease","volume":"40","author":"Deepak","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032411000531200_jjag035-B33","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.cgh.2024.07.007","article-title":"Live rotavirus vaccination appears low-risk in infants born to mothers with inflammatory bowel disease on biologics","volume":"23","author":"Ernest-Suarez","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026032411000531200_jjag035-B34","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.3389\/fimmu.2017.01123","article-title":"Immunological changes in blood of newborns exposed to anti-TNF-\u03b1 during pregnancy","volume":"8","author":"Esteve-Sol\u00e9","year":"2017","journal-title":"Front Immunol"},{"key":"2026032411000531200_jjag035-B35","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40264-019-00881-8","article-title":"Exposure to infliximab during pregnancy: post-marketing experience","volume":"43","author":"Geldhof","year":"2020","journal-title":"Drug Saf"},{"key":"2026032411000531200_jjag035-B36","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1177\/2050640620964619","article-title":"Infliximab clearance decreases in the second and third trimesters of pregnancy in inflammatory bowel disease","volume":"9","author":"Gri\u0161i\u0107","year":"2021","journal-title":"United European Gastroenterol J"},{"key":"2026032411000531200_jjag035-B37","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1002\/ueg2.12236","article-title":"Observational data from the adalimumab post-marketing PYRAMID registry of patients with Crohn\u2019s disease who became pregnant: a post hoc analysis","volume":"10","author":"Hart","year":"2022","journal-title":"United European Gastroenterol J"},{"key":"2026032411000531200_jjag035-B38","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1093\/ibd\/izz110","article-title":"Anti-TNF therapy in pregnant women with inflammatory bowel disease: effects of therapeutic strategies on disease behavior and birth outcomes","volume":"26","author":"Julsgaard","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2026032411000531200_jjag035-B39","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1097\/MIB.0000000000001102","article-title":"The effect of disease activity on birth outcomes in a nationwide cohort of women with moderate to severe inflammatory bowel disease","volume":"23","author":"Kammerlander","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"2026032411000531200_jjag035-B40","doi-asserted-by":"publisher","first-page":"2385","DOI":"10.1111\/j.1572-0241.2004.30186.x","article-title":"Outcome of pregnancy in women receiving infliximab for the treatment of Crohn\u2019s disease and rheumatoid arthritis","volume":"99","author":"Katz","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"2026032411000531200_jjag035-B41","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000493462","article-title":"Pregnancy outcomes of patients exposed to adalimumab in Japan","volume":"37","author":"Kawai","year":"2019","journal-title":"Dig Dis"},{"key":"2026032411000531200_jjag035-B42","doi-asserted-by":"publisher","first-page":"20","DOI":"10.14735\/amgh201820","article-title":"Pregnancy outcomes in women with inflammatory bowel disease treated with biosimilar infliximab","volume":"72","author":"Kolar","year":"2018","journal-title":"Gastroent Hepatol"},{"key":"2026032411000531200_jjag035-B43","doi-asserted-by":"publisher","first-page":"139","DOI":"10.5217\/ir.2016.14.2.139","article-title":"Pregnancy outcome in women with inflammatory bowel disease treated with anti-tumor necrosis factor and\/or thiopurine therapy: a multicenter study from Japan","volume":"14","author":"Komoto","year":"2016","journal-title":"Intest Res"},{"key":"2026032411000531200_jjag035-B44","doi-asserted-by":"publisher","first-page":"237","DOI":"10.5217\/ir.2018.00071","article-title":"Influence of anti-tumor necrosis factor-alpha therapy to pregnant inflammatory bowel disease women and their children\u2019s immunity","volume":"17","author":"Lee","year":"2019","journal-title":"Intest Res"},{"key":"2026032411000531200_jjag035-B45","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1038\/s41395-018-0176-7","article-title":"Continuous anti-TNF\u03b1 use throughout pregnancy: possible complications for the mother but not for the fetus. A retrospective cohort on the French National Health Insurance Database (EVASION)","volume":"113","author":"Luu","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2026032411000531200_jjag035-B46","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1093\/ibd\/izab227","article-title":"Anti-TNF\u03b1 induction therapy for patients with active inflammatory bowel disease during pregnancy: A case series","volume":"28","author":"MacIsaac","year":"2022","journal-title":"Inflamm Bowel Dis"},{"key":"2026032411000531200_jjag035-B47","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1365-2036.2005.02405.x","article-title":"Intentional infliximab use during pregnancy for induction or maintenance of remission in Crohn\u2019s disease","volume":"21","author":"Mahadevan","year":"2005","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032411000531200_jjag035-B48","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1111\/apt.13960","article-title":"Vedolizumab exposure in pregnancy: outcomes from clinical studies in inflammatory bowel disease","volume":"45","author":"Mahadevan","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032411000531200_jjag035-B49","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1111\/apt.16448","article-title":"Comparative study of pregnancy outcomes in women with inflammatory bowel disease treated with thiopurines and\/or anti-TNF: a French nationwide study 2010-2018","volume":"54","author":"Meyer","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032411000531200_jjag035-B50","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1016\/j.cgh.2023.12.029","article-title":"Safety of Vedolizumab and Ustekinumab compared with anti-TNF in pregnant women with inflammatory bowel disease","volume":"23","author":"Meyer","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026032411000531200_jjag035-B51","doi-asserted-by":"publisher","first-page":"90","DOI":"10.5217\/ir.2017.15.1.90","article-title":"Maternal and fetal outcomes in pregnant Japanese women with inflammatory bowel disease: our experience with a series of 23 cases","volume":"15","author":"Minami","year":"2017","journal-title":"Intest Res"},{"key":"2026032411000531200_jjag035-B52","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1111\/apt.15539","article-title":"Pregnancy outcomes in inflammatory bowel disease patients treated with vedolizumab, anti-TNF or conventional therapy: results of the European CONCEIVE study","volume":"51","author":"Moens","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032411000531200_jjag035-B53","doi-asserted-by":"publisher","first-page":"100518","DOI":"10.1016\/j.ajogmf.2021.100518","article-title":"Exposure to biologic therapy and associated maternal and neonatal outcomes in pregnancies complicated by inflammatory bowel disease","volume":"4","author":"Rekawek","year":"2022","journal-title":"Am J Obstet Gynecol MFM"},{"key":"2026032411000531200_jjag035-B54","doi-asserted-by":"publisher","first-page":"426","DOI":"10.23922\/jarc.2021-021","article-title":"Safety prediction of infants born to mothers with Crohn\u2019s disease treated with biological agents in the late gestation period","volume":"5","author":"Sako","year":"2021","journal-title":"J Anus Rectum Colon"},{"key":"2026032411000531200_jjag035-B55","doi-asserted-by":"publisher","first-page":"1846","DOI":"10.1002\/ibd.21583","article-title":"Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy","volume":"17","author":"Schnitzler","year":"2011","journal-title":"Inflamm Bowel Dis"},{"key":"2026032411000531200_jjag035-B56","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1111\/apt.12833","article-title":"Factors associated with pregnancy outcome in anti-TNF treated women with inflammatory bowel disease","volume":"40","author":"Seirafi","year":"2014","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032411000531200_jjag035-B57","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1111\/apt.14040","article-title":"The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease","volume":"45","author":"Seow","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032411000531200_jjag035-B58","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.2169\/internalmedicine.4347-24","article-title":"Ulcerative colitis in pregnancy: a Japanese multicenter cohort study focusing on their mutual influence","volume":"64","author":"Shimodate","year":"2025","journal-title":"Intern Med"},{"key":"2026032411000531200_jjag035-B59","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1111\/jgh.16549","article-title":"Prescribing in pregnant women with inflammatory bowel disease and its relationship to congenital malformations in Japan","volume":"39","author":"Takahashi","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"key":"2026032411000531200_jjag035-B60","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1093\/ibd\/izz250","article-title":"Early discontinuation of infliximab in pregnant women with inflammatory bowel disease","volume":"26","author":"Truta","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"2026032411000531200_jjag035-B61","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1093\/ibd\/izad316","article-title":"Preterm birth and in utero exposure to corticosteroids are associated with increased infection risk in children of mothers With IBD","volume":"30","author":"Vestergaard","year":"2024","journal-title":"Inflamm Bowel Dis"},{"key":"2026032411000531200_jjag035-B62","doi-asserted-by":"publisher","first-page":"935034","DOI":"10.3389\/fped.2022.935034","article-title":"Immune function in newborns with in-utero exposure to anti-TNF\u03b1 therapy","volume":"10","author":"Weiss","year":"2022","journal-title":"Front Pediatr"},{"key":"2026032411000531200_jjag035-B63","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/apt.16192","article-title":"Safety of ustekinumab or vedolizumab in pregnant inflammatory bowel disease patients: a multicentre cohort study","volume":"53","author":"Wils","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032411000531200_jjag035-B64","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1111\/apt.17224","article-title":"Ustekinumab during pregnancy in patients with inflammatory bowel disease: a prospective multicentre cohort study","volume":"56","author":"Avni-Biron","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032411000531200_jjag035-B65","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.14309\/ajg.0000000000000186","article-title":"Exposure to Vedolizumab in IBD pregnant women appears of low risk for mother and neonate: a first prospective comparison study","volume":"114","author":"Bar-Gil Shitrit","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"2026032411000531200_jjag035-B66","doi-asserted-by":"publisher","first-page":"951","DOI":"10.3109\/00365521.2013.812141","article-title":"Pregnancy and newborn outcome of mothers with inflammatory bowel diseases exposed to anti-TNF-\u03b1 therapy during pregnancy: three-center study","volume":"48","author":"Bortlik","year":"2013","journal-title":"Scand J Gastroenterol"},{"key":"2026032411000531200_jjag035-B67","doi-asserted-by":"publisher","first-page":"e0223603","DOI":"10.1371\/journal.pone.0223603","article-title":"Birth outcomes in women who have taken adalimumab in pregnancy: A prospective cohort study","volume":"14","author":"Chambers","year":"2019","journal-title":"PLoS One"},{"key":"2026032411000531200_jjag035-B68","doi-asserted-by":"publisher","DOI":"10.14309\/ajg.0000000000003593","article-title":"Birth outcomes in women who have taken vedolizumab in pregnancy: results from the vedolizumab pregnancy exposure registry","author":"Chambers","year":"2025","journal-title":"Am J Gastroenterol"},{"key":"2026032411000531200_jjag035-B69","doi-asserted-by":"publisher","first-page":"1759720X221087650","DOI":"10.1177\/1759720X221087650","article-title":"Pharmacovigilance pregnancy data in a large population of patients with chronic inflammatory disease exposed to certolizumab pegol","volume":"14","author":"Clowse","year":"2022","journal-title":"Ther Adv Musculoskelet Dis"},{"key":"2026032411000531200_jjag035-B70","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1136\/gutjnl-2015-309321","article-title":"Tailored anti-TNF therapy during pregnancy in patients with IBD: maternal and fetal safety","volume":"65","author":"de Lima","year":"2016","journal-title":"Gut"},{"key":"2026032411000531200_jjag035-B71","doi-asserted-by":"publisher","first-page":"1320","DOI":"10.1111\/apt.16593","article-title":"Vedolizumab clearance in neonates, susceptibility to infections and developmental milestones: a prospective multicentre population-based cohort study","volume":"54","author":"Julsgaard","year":"2021","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032411000531200_jjag035-B72","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.cgh.2024.01.008","article-title":"Infant ustekinumab clearance, risk of infection, and development after exposure during pregnancy","volume":"23","author":"Julsgaard","year":"2025","journal-title":"Clin Gastroenterol Hepatol off Clin Pract J Am Gastroenterol Assoc"},{"key":"2026032411000531200_jjag035-B73","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1093\/ecco-jcc\/jjy058","article-title":"Anti-TNF Levels in cord blood at birth are associated with anti-TNF Type","volume":"12","author":"Kanis","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2026032411000531200_jjag035-B74","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1136\/gutjnl-2019-319129","article-title":"Health outcomes of 1000 children born to mothers with inflammatory bowel disease in their first 5 years of life","volume":"70","author":"Kanis","year":"2021","journal-title":"Gut"},{"key":"2026032411000531200_jjag035-B75","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1111\/imj.13057","article-title":"Safe and effective: anti-tumour necrosis factor therapy use in pregnant patients with Crohn disease and ulcerative colitis","volume":"46","author":"Kiely","year":"2016","journal-title":"Intern Med J"},{"key":"2026032411000531200_jjag035-B76","doi-asserted-by":"publisher","first-page":"1678","DOI":"10.1038\/s41395-018-0202-9","article-title":"Pregnancy outcomes reported during the 13-Year TREAT registry: a descriptive report","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"2026032411000531200_jjag035-B77","doi-asserted-by":"publisher","first-page":"e00795","DOI":"10.14309\/ctg.0000000000000795","article-title":"Use of biosimilars to infliximab during pregnancy in women with inflammatory bowel disease: results from the pregnancy in inflammatory bowel disease and neonatal outcomes study","volume":"15","author":"Long","year":"2024","journal-title":"Clin Transl Gastroenterol"},{"key":"2026032411000531200_jjag035-B78","doi-asserted-by":"publisher","first-page":"2494","DOI":"10.1093\/ibd\/izy160","article-title":"Outcomes of pregnancies with maternal\/paternal exposure in the tofacitinib safety databases for ulcerative colitis","volume":"24","author":"Mahadevan","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"2026032411000531200_jjag035-B79","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1053\/j.gastro.2020.11.038","article-title":"Pregnancy and neonatal outcomes after fetal exposure to biologics and thiopurines among women with inflammatory bowel disease","volume":"160","author":"Mahadevan","year":"2021","journal-title":"Gastroenterology"},{"key":"2026032411000531200_jjag035-B80","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1111\/apt.16960","article-title":"Pregnancy outcomes following periconceptional or gestational exposure to ustekinumab: review of cases reported to the manufacturer\u2019s global safety database","volume":"56","author":"Mahadevan","year":"2022","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032411000531200_jjag035-B81","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s40264-024-01454-0","article-title":"Pregnancy outcomes in patients treated with upadacitinib: analysis of data from clinical trials and postmarketing reports","volume":"47","author":"Mahadevan","year":"2024","journal-title":"Drug Saf"},{"key":"2026032411000531200_jjag035-B82","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1093\/ecco-jcc\/jjac086","article-title":"Safety of ustekinumab and vedolizumab during pregnancy-pregnancy, neonatal, and infant outcome: a prospective multicentre study","volume":"16","author":"Mitrova","year":"2022","journal-title":"J Crohns Colitis"},{"key":"2026032411000531200_jjag035-B83","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.cgh.2024.01.019","article-title":"Tofacitinib in pregnancy: assessing pregnancy and infant outcomes, cord blood, and breast milk concentrations","volume":"23","author":"Mitrova","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026032411000531200_jjag035-B84","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.cgh.2024.02.025","article-title":"Vedolizumab and ustekinumab levels in pregnant women with inflammatory bowel disease and infants exposed in utero","volume":"23","author":"Prentice","year":"2025","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026032411000531200_jjag035-B85","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1053\/j.gastro.2025.03.016","article-title":"Active inflammatory bowel disease on intestinal ultrasound during pregnancy is associated with an increased risk of adverse pregnancy and neonatal outcomes independent of clinical and biochemical disease activity","volume":"169","author":"Prentice","year":"2025","journal-title":"Gastroenterology"},{"key":"2026032411000531200_jjag035-B86","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.gastha.2022.04.009","article-title":"Outcomes of continuation vs discontinuation of adalimumab therapy during third trimester of pregnancy in inflammatory bowel disease","volume":"1","author":"Truta","year":"2022","journal-title":"Gastro Hep Adv"},{"key":"2026032411000531200_jjag035-B87","doi-asserted-by":"publisher","DOI":"10.1007\/s12664-024-01657-4","article-title":"Pregnancy outcomes among women with inflammatory bowel disease: a UK tertiary centre experience","author":"Tunney","year":"2024","journal-title":"Indian J Gastroenterol"},{"key":"2026032411000531200_jjag035-B88","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.cgh.2012.10.024","article-title":"Effects of discontinuing anti-tumor necrosis factor therapy during pregnancy on the course of inflammatory bowel disease and neonatal exposure","volume":"11","author":"Zelinkova","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2026032411000531200_jjag035-B89","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1007\/s10620-015-3992-2","article-title":"The effect of maternal peripartum anti-TNF\u03b1 use on infant immune response","volume":"61","author":"Sheibani","year":"2016","journal-title":"Dig Dis Sci"},{"key":"2026032411000531200_jjag035-B90","doi-asserted-by":"publisher","first-page":"l869","DOI":"10.1136\/bmj.l869","article-title":"Role of maternal age and pregnancy history in risk of miscarriage: prospective register based study","volume":"364","author":"Magnus","year":"2019","journal-title":"BMJ"},{"key":"2026032411000531200_jjag035-B91","doi-asserted-by":"publisher","first-page":"2162","DOI":"10.1016\/S0140-6736(12)60820-4","article-title":"National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications","volume":"379","author":"Blencowe","year":"2012","journal-title":"Lancet"},{"key":"2026032411000531200_jjag035-B92","first-page":"1","article-title":"Infant mortality statistics from the 2013 period linked birth\/infant death data set","volume":"64","author":"Matthews","year":"2015","journal-title":"Natl Vital Stat Rep Cent Dis Control Prev Natl Cent Health Stat Natl Vital Stat Syst"},{"key":"2026032411000531200_jjag035-B93","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ejogrb.2004.03.007","article-title":"Risk factors for low birth weight: a review","volume":"116","author":"Valero De Bernab\u00e9","year":"2004","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2026032411000531200_jjag035-B94","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1007\/s12687-018-0384-2","article-title":"Estimating the birth prevalence and pregnancy outcomes of congenital malformations worldwide","volume":"9","author":"Moorthie","year":"2018","journal-title":"J Community Genet"},{"key":"2026032411000531200_jjag035-B95","doi-asserted-by":"publisher","first-page":"e001608","DOI":"10.1136\/bmjph-2024-001608","article-title":"Global and regional burden of congenital birth defects, 1990-2021: persistent healthcare disparities and emerging challenges from non-fatal health burden","volume":"3","author":"Duan","year":"2025","journal-title":"BMJ Public Health"},{"key":"2026032411000531200_jjag035-B96","doi-asserted-by":"publisher","first-page":"1862","DOI":"10.1111\/1471-0528.13946","article-title":"Inflammatory bowel disease in pregnancy: a population-based study of prevalence and pregnancy outcomes","volume":"123","author":"Shand","year":"2016","journal-title":"BJOG"},{"key":"2026032411000531200_jjag035-B97","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1111\/apt.15587","article-title":"Systematic review with meta-analysis: risk of adverse pregnancy-related outcomes in inflammatory bowel disease","volume":"51","author":"Tandon","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"2026032411000531200_jjag035-B98","doi-asserted-by":"publisher","first-page":"1539","DOI":"10.3748\/wjg.v29.i10.1539","article-title":"Precision medicine in inflammatory bowel disease: Individualizing the use of biologics and small molecule therapies","volume":"29","author":"Cheah","year":"2023","journal-title":"World J Gastroenterol"},{"key":"2026032411000531200_jjag035-B99","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.3389\/fmicb.2019.01924","article-title":"The impact of infection in pregnancy on placental vascular development and adverse birth outcomes","volume":"10","author":"Weckman","year":"2019","journal-title":"Front Microbiol"},{"key":"2026032411000531200_jjag035-B100","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1080\/17474124.2025.2577985","article-title":"Clinical management of inflammatory bowel disease from preconception to postpartum","volume":"19","author":"Rabinowitz","year":"2025","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"2026032411000531200_jjag035-B101","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/jgh.70148","article-title":"The impact of disease activity and medications on pregnancy and fetal outcomes in women with inflammatory bowel disease: a cohort study from the IBD-ME group","volume":"41","author":"Mosli","year":"2026","journal-title":"J Gastroenterol Hepatol"},{"key":"2026032411000531200_jjag035-B102","doi-asserted-by":"publisher","first-page":"e0186287","DOI":"10.1371\/journal.pone.0186287","article-title":"Advanced maternal age and adverse pregnancy outcomes: a systematic review and meta-analysis","volume":"12","author":"Lean","year":"2017","journal-title":"PLoS One"},{"key":"2026032411000531200_jjag035-B103","doi-asserted-by":"publisher","first-page":"380","DOI":"10.5468\/ogs.24005","article-title":"The influence of advanced maternal age on congenital malformations, short- and long-term outcomes in offspring of nulligravida: a Korean National Cohort Study over 15 years","volume":"67","author":"You","year":"2024","journal-title":"Obstet Gynecol Sci"},{"key":"2026032411000531200_jjag035-B104","doi-asserted-by":"publisher","DOI":"10.3390\/life13020475","article-title":"Pregnancy in patients with inflammatory bowel diseases\u2014a literature review","volume":"13","author":"Grigorescu","year":"2023","journal-title":"Life (Basel)"},{"key":"2026032411000531200_jjag035-B105","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1097\/MIB.0000000000000802","article-title":"Adverse pregnancy outcomes among women with inflammatory bowel disease: a population-based study from England","volume":"22","author":"Abdul Sultan","year":"2016","journal-title":"Inflamm Bowel Dis"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/3\/jjag035\/67499735\/jjag035.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/20\/3\/jjag035\/67499735\/jjag035.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T15:00:13Z","timestamp":1774364413000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/doi\/10.1093\/ecco-jcc\/jjag035\/8539729"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":105,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3,10]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjag035","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,3]]},"published":{"date-parts":[[2026,3]]},"article-number":"jjag035"}}